Peer Review reports
From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
| Original Submission | ||
|---|---|---|
| 21 Feb 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 19 Mar 2022 | Reviewed | Reviewer Report |
| 6 Apr 2022 | Reviewed | Reviewer Report - Linda Fryklund |
| 22 May 2022 | Author responded | Author comments - Huifeng Yun |
| Resubmission - Version 3 | ||
| 22 May 2022 | Submitted | Manuscript version 3 |
| 25 May 2022 | Author responded | Author comments - Huifeng Yun |
| Resubmission - Version 4 | ||
| 25 May 2022 | Submitted | Manuscript version 4 |
| 30 May 2022 | Author responded | Author comments - Huifeng Yun |
| Resubmission - Version 5 | ||
| 30 May 2022 | Submitted | Manuscript version 5 |
| 16 Jun 2022 | Reviewed | Reviewer Report - Linda Fryklund |
| 22 Jun 2022 | Reviewed | Reviewer Report |
| 20 Jul 2022 | Author responded | Author comments - Huifeng Yun |
| Resubmission - Version 6 | ||
| 20 Jul 2022 | Submitted | Manuscript version 6 |
| Publishing | ||
| 22 Jul 2022 | Editorially accepted | |
| 1 Nov 2022 | Article published | 10.1186/s41927-022-00295-7 |
You can find further information about peer review here.